Importantly, VitD/cisplatin co-treatment was most potent in upregulating Bim (Figure 5b), providing a molecular explanation for the efficient cancer cell-killing activity we discovered, even for cisplatin-resistant cells. This evidence concerns the gene BCL2L11 and cancer.